Search research articles
Contact Us
Filters
Showing results (41-50 of 53) with videos related to
Page
of 6
Sort By:
JCO Oncology Practice
|
September 30, 2024
Using Oncology Treatment Pathway Data to Evaluate Serious Illness Communication, Care Utilization, and End-of-Life Care for Patients With Cancer
Cody E Cotner, Angela C Tramontano, Alex Post, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 10, 2016
A Prospective Evaluation of Circulating Tumor Cells and Cell-Free DNA in EGFR-Mutant Non-Small Cell Lung Cancer Patients Treated with Erlotinib on a Phase II Trial
Masahiko Yanagita, Amanda J Redig, Cloud P Paweletz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 6, 2016
MET Exon 14 Mutations in Non-Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression
Mark M Awad, Geoffrey R Oxnard, David M Jackman, et al.
Lung Cancer (Amsterdam, Netherlands)
|
December 19, 2016
Radiologic-pathologic correlation of response to chemoradiation in resectable locally advanced NSCLC
Vishesh Agrawal, Thibaud P Coroller, Ying Hou, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
June 15, 2026
Pathways to Advance Targeted and Helpful Serious Illness Conversations (PATH-SIC): A Randomized Clinical Trial
Christopher R Manz, Cody E Cotner, Angela C Tramontano, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 5, 2008
Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib
Daniel B Costa, Kim-Son H Nguyen, Byoung C Cho, et al.
Lung Cancer (Amsterdam, Netherlands)
|
June 30, 2014
Aggressive therapy for patients with non-small cell lung carcinoma and synchronous brain-only oligometastatic disease is associated with long-term survival
Phillip J Gray, Raymond H Mak, Beow Y Yeap, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 18, 2007
Phase II clinical trial of chemotherapy-naive patients > or = 70 years of age treated with erlotinib for advanced non-small-cell lung cancer
David M Jackman, Beow Y Yeap, Neal I Lindeman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 5, 2006
Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib
David M Jackman, Beow Y Yeap, Lecia V Sequist, et al.
JCO Precision Oncology
|
December 18, 2024
Phase II Study of Defactinib (VS6063) in Patients With Tumors With <i>NF2</i> Loss: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol U
Marjorie G Zauderer, Opeyemi Jegede, David M Jackman, et al.
Page
of 6
Search research articles
Search
Showing results (41-50 of 53) with videos related to
Sort By:
Page
of 6
JCO Oncology Practice
|
September 30, 2024
Using Oncology Treatment Pathway Data to Evaluate Serious Illness Communication, Care Utilization, and End-of-Life Care for Patients With Cancer
Cody E Cotner, Angela C Tramontano, Alex Post, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 10, 2016
A Prospective Evaluation of Circulating Tumor Cells and Cell-Free DNA in EGFR-Mutant Non-Small Cell Lung Cancer Patients Treated with Erlotinib on a Phase II Trial
Masahiko Yanagita, Amanda J Redig, Cloud P Paweletz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 6, 2016
MET Exon 14 Mutations in Non-Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression
Mark M Awad, Geoffrey R Oxnard, David M Jackman, et al.
Lung Cancer (Amsterdam, Netherlands)
|
December 19, 2016
Radiologic-pathologic correlation of response to chemoradiation in resectable locally advanced NSCLC
Vishesh Agrawal, Thibaud P Coroller, Ying Hou, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
June 15, 2026
Pathways to Advance Targeted and Helpful Serious Illness Conversations (PATH-SIC): A Randomized Clinical Trial
Christopher R Manz, Cody E Cotner, Angela C Tramontano, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 5, 2008
Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib
Daniel B Costa, Kim-Son H Nguyen, Byoung C Cho, et al.
Lung Cancer (Amsterdam, Netherlands)
|
June 30, 2014
Aggressive therapy for patients with non-small cell lung carcinoma and synchronous brain-only oligometastatic disease is associated with long-term survival
Phillip J Gray, Raymond H Mak, Beow Y Yeap, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 18, 2007
Phase II clinical trial of chemotherapy-naive patients > or = 70 years of age treated with erlotinib for advanced non-small-cell lung cancer
David M Jackman, Beow Y Yeap, Neal I Lindeman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 5, 2006
Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib
David M Jackman, Beow Y Yeap, Lecia V Sequist, et al.
JCO Precision Oncology
|
December 18, 2024
Phase II Study of Defactinib (VS6063) in Patients With Tumors With <i>NF2</i> Loss: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol U
Marjorie G Zauderer, Opeyemi Jegede, David M Jackman, et al.
Page
of 6